Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors

Oncologist

Volumn 18, Issue 8, 2013, Pages 900-908

  Lenihan, Daniel J ^a   Kowey, Peter R ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Adverse events; Cancer; Cardiac; Cardiovascular; TKIs; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; LAPATINIB; LETROZOLE; NILOTINIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; VANDETANIB;

ADJUVANT THERAPY; ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TORSADE DES POINTES;

ADVERSE EVENTS; CANCER; CARDIAC; CARDIOVASCULAR; TKIS; TYROSINE KINASE INHIBITORS;

CARDIOVASCULAR DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEART FAILURE; HUMANS; HYPERTENSION; NEOPLASMS; PROTEIN KINASE INHIBITORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84883238548     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0466     Document Type: Article

References (58)

1. Lenihan DJ. Tyrosine kinase inhibitors: Can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol 2008;26:5154-5155.
2. Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 2010;53:114-120.
3. Chen MH, Kerkela R, Force T. Mechanisms of cardiomyopathyassociatedwithtyrosinekinaseinhibitor cancer therapeutics. Circulation 2008;118:84-95.
4. Chen MH. Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Curr Cardiol Rep 2009;11:167-174.
5. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-3371.
6. Khakoo AY, Yeh ETH. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008;5:655-667.
7. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
8. Kim TD, le Coutre P, SchwarzMet al. Clinical cardiac safety profile of nilotinib. Haematologica 2012; 97:883-889.
9. Hossain A, Chen A, Ivy P et al. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: Updating the common terminology criteria for clinical trial reporting. Heart Fail Clin 2011;7:373-384.
10. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
11. National Cancer Institute. Common Terminology Criteria for Adverse Events v 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf. Accessed May 13, 2013.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events v 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_ 4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed May 13, 2013.
13. National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: http:// www.nhlbi.nih.gov/guidelines/hypertension/ jnc7full.htm. Accessed May 13, 2013.
14. National Heart Lung and Blood Institute. The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8). Available at: http:// www.nhlbi.nih.gov/guidelines/hypertension/jnc8/ index.htm. Accessed May 13, 2013.
15. Schall R, Ring A. Statistical characterization of QT prolongation. J Biopharm Stat 2010;20:543-562.
16. Caprelsa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2012. Available at: http://www.astrazeneca-us.com.
17. Sutent [package insert]. New York, NY: Pfizer Inc; 2012. Available at: http://www.pfizer.com.
18. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012. Available at: http://www.novartis.com.
19. Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012. Available at: http://www.gsk.com/.
20. Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012. Available at: http://www.gsk.com/.
21. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2011. Available at: http://www.bayer.com.
22. Cometriq [package insert]. South San Francisco, CA: Exelixis, Inc.; 2012. Available at: http:// www.exelixis.com/.
23. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; 2012. Available at: http:// www.gene.com/.
24. Herceptin [package insert]. South San Francisco, CA: Genentech, Inc.; 2010. Available at: http://www.gene.com/.
25. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
26. Schutz FA, Je Y, Richards CJ et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30:871-877.
27. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
28. Mourad JJ, des Guetz G, DebbabiHet al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927-934.
29. Steeghs N, Gelderblom H, Roodt JO et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008;14:3470-3476.
30. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-658.
31. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-1369.
32. Kerkela R, Woulfe KC, Durand J-B et al. Sunitinib-induced cardiotoxicity is mediated by offtarget inhibition of AMP-activated protein kinase. Clin Transl Sci 2009;2:15-25.
33. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
34. Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov Today 2008; 13:778-784.
35. Kerkela R, Grazette L, YacobiRet al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
36. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
37. Hunt SA, Abraham WT, ChinMHet al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
38. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-2262.
39. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: Clinical relevanceandresponse to pharmacologic therapy. JAm Coll Cardiol 2010;55:213-220.
40. Noori A, Lindenfeld J, Wolfel E et al. Betablockade in adriamycin-induced cardiomyopathy. J Card Fail 2000;6:115-119.
41. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology Cardiovasc Res 2000;47:219-233.
42. Brell JM. Prolonged QTc interval in cancer therapeutic drug development: Defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 2010;53: 164-172.
43. Anderson ME, Al-Khatib SM, Roden DM et al. Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002;144: 769-781.
44. Al-Khatib SM, Allen LaPointe NM, Kramer JM et al. What clinicians should know about the QT interval. JAMA 2003;289:2120-2127.
45. Taran LM, Szilagyi N. The duration of the electrical systole (Q-T) in acute rheumatic carditis in children. AmHeart J 1947;33:14-26.
46. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 2003;8:343-351.
47. Sagie A, Larson MG, Goldberg RJ et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). AmJ Cardiol 1992;70:797-801.
48. Desai M, Li L, Desta Z et al. Variability of heart rate correction methods for theQTinterval. Br J Clin Pharmacol 2003;55:511-517.
49. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: http://www.fda.gov/downloads/Regulatory Information/Guidances/ucm129357.pdf. Accessed May 13, 2013.
50. Drew BJ, Califf RM, Funk M et al. Practice standards for electrocardiographic monitoring in hospital settings: An American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: Endorsed by the International Society ofComputerizedElectrocardiology and the American Association of Critical-Care Nurses Circulation 2004;110:2721-2746.
51. U.S. Department of Health and Human Services. Votrient (pazopanib) Supplement Approval Release REMS Requirement. Available at: http:// www.accessdata.fda.gov/drugsatfda_docs/appletter/ 2011/022465s006ltr.pdf. AccessedMay13, 2013.
52. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS). Tasigna (nilotinib). Available at: http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM217737.pdf. Accessed May13,2013.
53. U.S. Department of Health andHumanServices. Sutent (sunitinib) Supplement Approval Release REMS Requirement. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/appletter/2011/ 021938s013, s017, s018ltr.pdf.AccessedMay13,2013.
54. U.S. Food and Drug Administration. Caprelsa (vandetanib) Risk Evaluation and Mitigation Strategy (REMS). Available at: http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM253441.pdf. Accessed December6,2012.
55. CredibleMeds. Drug Lists by Risk Groups: Drugs that Prolong the QT Interval and/or Induce Torsades de Pointes. Available at: http://www. azcert.org/medical-pros/drug-lists/drug-lists.cfm. Accessed May 13, 2013.
56. CredibleMeds. Clinically Important Drug Interactions. Available at: http://www.azcert.org/ medical-pros/druginteractions.cfm. Accessed May 13, 2013.
57. Kubota T, Shimizu W, Kamakura S et al. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol 2000;11:1048-1054.
58. Kulkarni P, Bhattacharya S, Petros AJ. Torsade de pointes and long QT syndrome following major blood transfusion. Anaesthesia 1992;47:125-127.